Recent Advances in Antimicrobial Nano-Drug Delivery Systems
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: closed (20 November 2024) | Viewed by 283
Special Issue Editor
Interests: nanotechnology; cancer; nanostructures; biochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In this century, infectious illnesses are significant public health concerns. The widespread utilization of antimicrobial compounds throughout recent years has played a role in the spread of multi-drug-resistant microorganisms. According to a recent World Health Organization report, grappling with antibacterial (ATB) drug resistance and the creation of durable ATBs poses a substantial challenge. As pathogens swiftly adapt and evolve through various mechanisms; conventional ATBs frequently lead to only temporarily effective or ineffective treatments. Consequently, there is a growing interest in novel therapeutic approaches, such as those based on nano-drug delivery systems (NDDS) and nanoparticles with intrinsic antimicrobial activity, due to their potential to enhance drug bioavailability, improve targeting, and overcome the resistance mechanisms. These can include nanoemulsions, liposomes, nanostructured lipid carriers, solid lipid nanoparticles, polymeric nanoparticles, metal nanoparticles, and others. Acknowledging the importance of this subject matter, this Special Issue endeavors to curate the recent strides in nanomedicine specifically tailored to the maladies caused by microorganisms.
Prof. Dr. Luís Alexandre Muehlmann
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- infectious diseases
- antimicrobial resistance
- antibiotics
- antifungal drugs
- nanostructures
- pathogen adaptation
- nanomedicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
